TransMedics Reports Third Quarter 2023 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P, Dow edge higher on Mideast deal hopes; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
TransMedics (TMDX) surges 40% after raising sales forecast
November 7, 2023 6:53 AM ESTTransMedics Group (NASDAQ: TMDX) saw its stock rise more than 40% in pre-market Tuesday trading after the organ transplant company raised its full-year sales forecast.
In addition to the improved outlook, the health-care firm reported third-quarter revenue that exceeded the average analyst... More
TransMedics Group (TMDX) surges 30% on strong revenue beat and guidance
November 6, 2023 4:21 PM ESTTransMedics Group (NASDAQ: TMDX) surges after strong Q3 revenue beat and raised FY revenue guidance:
reported Q3 EPS of ($0.78), $0.62 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $66.4 million versus the consensus estimate of $49.19 million.sees FY 2023... MoreTransMedics Group (TMDX) Q3 Revenue Beat; Raises FY Revenue Guidance
November 6, 2023 4:20 PM ESTTransMedics Group (NASDAQ: TMDX) reported Q3 EPS of ($0.78), $0.62 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $66.4 million versus the consensus estimate of $49.19 million.
GUIDANCE:
TransMedics Group sees FY2023 revenue of $222-230 million, versus prior of... More
